AI Article Synopsis
- Dysregulated microRNAs are linked to gastric cancer, affecting processes like cell cycle, apoptosis, and invasion, with a focus on the role of miR-367.
- The study analyzed the expression of miR-367 in 37 gastric cancer patients and its impact on cancer cell lines, revealing a significant reduction of miR-367 in cancer tissues and its correlation with tumor characteristics.
- Overexpression of miR-367 decreased cell migration and invasion, identifying Rab23 as its target gene, suggesting that miR-367 could be a promising therapeutic agent for gastric cancer.
Article Abstract
Background: Dysregulated expression of microRNAs is often found in gastric cancer, and it contributes to the pathogenesis of gastric cancer via regulation of the cell cycle, proliferation, apoptosis, migration, and invasion.
Aim: In this study, we aimed to investigate the role of miR-367 in the invasion and metastasis of gastric cancer.
Methods: The correlation between the expression level of miR-367 and the clinicopathologic features of 37 patients with gastric cancer was analyzed by using real-time polymerase chain reaction (RT-PCR). In addition, we investigated the effect of miR-367 on the invasion and migration of the gastric cancer cell lines HS746T and SGC-7901 using transwell and scratch-wound assays, and the target gene of miR-367 was predicated and demonstrated by the bioinformatics method and luciferase reporter system, respectively.
Results: The results showed that the expression of miR-367 was significantly reduced in the gastric cancer tissues compared with the paraneoplastic tissues, and significantly correlated with the differentiation level, tumor-node-metastasis (TNM) stage, and metastasis of gastric cancer. Notably, the overexpression of miR-367 in gastric cancer cells inhibited the cellular migration and invasion. Furthermore, the luciferase reporter system demonstrated that Rab23 was a target gene of miR-367, and ectopic expression of Rab23 could reverse the invasion and migration inhibitory activity of miR-367.
Conclusions: Our study shows that miR-367 is a key negative regulator of the invasion and metastasis of gastric cancer and establishes a strong rationale for developing miR-367 as a novel therapeutic agent against gastric cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/gtmb.2014.0210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative genomic analysis unveiling the mutational landscape associated with premalignant lesions and early-stage gastric cardia cancer.
Medicine (Baltimore)
January 2025
Department of Endoscopy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
This study enrolled 10 patients diagnosed with premalignant lesions and early-stage gastric cardia adenocarcinoma (GCA), confirmed through endoscopic examination. These patients were subjected to next-generation sequencing (NGS) using a customized 1123-gene panel to identify genetic alterations and signaling pathways. The results were compared to stage IIB to IV GCA samples from the cancer genome atlas (TCGA) and a cohort of Hong Kong patients.
View Article and Find Full Text PDFPrimary solitary fibrous tumor of the stomach: A case report and a review of literature.
Medicine (Baltimore)
January 2025
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Rationale: Solitary fibrous tumors (SFTs) are spindle cell tumors that typically occur in the pleura and peritoneum, but very rarely in the stomach. To our best knowledge, there are only 10 cases reported in English literature. We reported a case of primary stomach SFT and summarized the characteristics of all previous cases, suggesting that pathologists and surgeons should include this disease in the differential diagnosis list of primary mesenchymal tumor of the stomach.
View Article and Find Full Text PDFArtificial Intelligence for Predicting HER2 Status of Gastric Cancer Based on Whole-Slide Histopathology Images: A Retrospective Multicenter Study.
Adv Sci (Weinh)
January 2025
Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC) shows a robust response to the combined therapy based HER2-targeted therapy. The application of these therapies is highly dependent on the evaluation of tumor HER2 status. However, there are many risks and challenges in HER2 assessment in GC.
View Article and Find Full Text PDFA comparison of the clinicopathological features and genetic alterations in stage II/III gastric cancer with no recurrence, early recurrence and late recurrence after curative surgery.
J Chin Med Assoc
November 2024
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Background: Few studies have explored the genetic changes and clinicopathological features of stage II/III gastric cancer (GC) patients with no tumor recurrence, early recurrence, or late recurrence after curative surgery.
Methods: In this study, 376 patients who underwent curative surgery for stage II/III GC were analyzed. The clinical and genetic features of patients with no recurrence, early recurrence (<2 years), and late recurrence (≥2 years) were compared.
Gastric and Esophageal Cancer in Pregnancy: A Review.
Obstet Gynecol Surv
December 2024
Professor, Obstetrics and Gynecology, University of Arkansas for the Medical Sciences, Little Rock, AR; Professor, Obstetrics and Gynecology, Virginia Tech Carilion School of Medicine, Roanoke, VA.
Importance: Upper gastrointestinal cancers such as gastric and esophageal cancers are rare malignancies with poor prognosis because it is usually diagnosed in latter stages. Presenting symptoms are frequently presumed pregnancy related rather than malignancy related. This review will raise awareness to consider these aggressive cancers in evaluating gastrointestinal complaints during pregnancy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!